Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients.

导出 LinkOut

翻译打印收藏纠错

作者： Ahmet Çağkan,İnkaya ^[1] ; Emre,Kara ^[2] ; Nursel Çalık,Başaran ^[3] ; Taha Koray,Şahin ^[3] ; Oğuz Abdullah,Uyaroğlu ^[1] ; Ömrüm,Uzun ^[1] ; Serhat,Ünal ^[1]

作者单位： Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. ^[1] Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey. ^[2] Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. ^[3]

主题词人类(Humans);尿酸(Uric Acid);次黄嘌呤磷酸核糖转移酶(Hypoxanthine Phosphoribosyltransferase);流感, 人(Influenza, Human)

DOI 10.3906/sag-2102-84

PMID 34392669

发布时间 2022-12-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Turkish journal of medical sciences

2021年51卷5期

2786-2788页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients.

Turkish journal of medical sciences

相似文献

Turkish journal of medical sciences

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients.

Turkish journal of medical sciences

相似文献

Turkish journal of medical sciences

相关期刊

检索历史清除